Edison Investment Research - Redhill Biopharma (RDHL) Second GI product added to commercial portfolio

Report

Edison Investment Research

Dr Jonas Peciulis

Second GI product added to commercial portfolio

Yesterday RedHill announced an agreement with US-based medical food developer and manufacturer Entera Health for exclusive rights to market EnteraGam in the US. In exchange, RedHill will pay tiered royalties, but notably no upfront or milestone payments. EnteraGam is an FDA-regulated medical food intended for the dietary management of chronic diarrhoea and has to be administered under medical supervision. This is the second product RedHill has added to its commercial portfolio after the co-promotion deal for Donnatal with Concordia Healthcare in January 2017.

06/04/2017 2 EN

Underlying

Redhill Biopharma

See profile

US7574681034 NASDAQ Stock Market Israel

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Dr Jonas Peciulis

Other Reports on these Companies

EQUITS GmbH

Solide Basis – Finanzierungsreichweite (Mitte 2025) bis zum angestrebten Studienabschluss von HDP 101 ausgeweitet

Wie erwartet, wurde die Finanzplanung vor dem Hintergrund der strategischen Zusammenarbeit mit dem Pharma-Multi Huadong Medicine (Huadong) und der abgeschlossenen Barkapitalerhöhung aktualisiert. Der Cash-Reach weitet sich deutlich auf „Mitte 2025“. Angestrebte zusätzliche Partnerschaften (jüngst mit Chiome Bioscience), wie auch angestrebte Erfolgsprämien aus dem Heritage-Portfolio sind darin nicht enthalten. Die Entwicklungsfortschritte in den ATAC®-Programmen bzw. in der wachsenden Zahl der Partnerprogramme validiert zum wiederholten Mal die Robustheit des Geschäftsmodells und verbessert da...

October 25, 2022 October 25, 2022 13 DE

EQS Group AG

DGAP-News: RedHill Biopharma veröffentlicht Highlights aus Q1/2022: Im Plan zu einem positiven operativen Cashflow in H2/22

DGAP-News: RedHill Biopharma Ltd. / Schlagwort(e): Quartalsergebnis RedHill Biopharma veröffentlicht Highlights aus Q1/2022: Im Plan zu einem positiven operativen Cashflow in H2/22 23.06.2022 / 13:05 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. RedHill Biopharma veröffentlicht Highlights aus Q1/2022: Im Plan zu einem positiven operativen Cashflow in H2/22 Ziel: Ein positiver operativer Cashflow ab H2/2022 -- Konzentration auf die Erreichung einer früher als erwarteten betrieblichen Rentabilität dank eines kürzlich umgesetzten umfassenden K...

June 23, 2022 June 23, 2022 1 DE

EQS Group AG

DGAP-News: RedHill gibt effektive Hemmung der Omikron-Variante durch seinen oralen COVID-19-Wirkstoffkandidaten Opaganib in vitro bekannt

DGAP-News: RedHill Biopharma Ltd. / Schlagwort(e): Studie 11.04.2022 / 15:49 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Korrektur zur Überschrift der Pressemitteilung von heute, 15:21 Uhr MESZ RedHill gibt effektive Hemmung der Omikron-Variante durch seinen oralen COVID-19-Wirkstoffkandidaten Opaganib in vitro bekannt Die beobachtete starke in-vitro-Aktivität von oralem Opaganib gegen Omikron ergänzt die zuvor beobachtete Hemmung der COVID-19 verursachenden Delta- und anderen SARS-CoV-2-Varianten; Die Untersuchungen wurden an der Universi...

April 11, 2022 April 11, 2022 1 DE

Headlam Group - Strategy for growth in tougher market

Headlam Group has laid out an ambitious long-term revenue target of between £900m and £1bn, as it seeks to grow its share of the UK floor coverings distributor market. Despite a challenging backdrop due to the low level of residential housing transactions, management is seeking to expand each of its sales channels: Trade Counters, Larger Customers, Regional Distribution and Europe & Other. The FY23 results reflected the more challenging environment and the group trades at a discount to its long-term average EV/sales multiple for FY24.

13h / 24m 13h / 24m 1 EN

Alison Turner

Alison Turner

Lithium Power International - Termination of coverage

Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

14h / 1m 14h / 1m 1 EN

Toby Thorrington

Toby Thorrington

paragon - Termination of coverage

14h / 1m 14h / 1m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN